15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 10 firms covering Krystal Biotech Inc, 9 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $284.00 to $403.00, a moderate spread. The average target of $349.22 sits 4% below the current $364.23. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $2.16 next quarter toward $9.87 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 ratings
Strong Buy
Strong Buy00%
Buy990%
Hold110%
Sell00%
Strong Sell00%
Based on 10 analysts giving stock ratings to Krystal Biotech Inc.
As of Jul, 9 of 10 firms rate KRYS a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
KRYS EPS & revenue forecast
EPS · NEXT QUARTER
$2.16
Range $1.42 – $4.12 · 8 analysts · -19% YoY
Next period, 8 analysts expect Krystal Biotech Inc to earn $2.16 a share (range $1.42 – $4.12), versus $2.66 a year earlier. Full-year consensus is $8.21, growing to $9.87 the year after.
REVENUE · NEXT QUARTER
$134.7M
Range $126.5M – $149.4M · 8 analysts · +38% YoY
Revenue is expected to reach $134.7M (range $126.5M – $149.4M), +37.7% year-over-year. Full-year consensus is $516.0M, rising to $670.2M next year.
Top analysts covering Krystal Biotech Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on KRYS.
#1
Geulah Livshits
Chardan Capital · Rank #100
Buy
$323.00-11.3% to target
Overall win rate
44%
+ Follow
#2
Yigal Nochomovitz
Citigroup · Rank #131
Buy
$378.00+3.8% to target
Overall win rate
43%
+ Follow
#3
Joseph Pantginis
HC Wainwright & Co. · Rank #266
Buy
$361.00-0.9% to target
Overall win rate
32%
+ Follow
#4
Alec Stranahan
B of A Securities
Buy
$396.00+8.7% to target
Coverage
—
+ Follow
#5
Ritu Baral
TD Cowen
Buy
$403.00+10.6% to target
Coverage
—
+ Follow
KRYS stock forecast FAQ
What is KRYS's average 12-month price target?+
The 9 analysts with a live target average $349.22 for Krystal Biotech Inc over the next 12 months, ranging from a $403.00 high to a $284.00 low.
Is KRYS stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 10 analyst ratings, 9 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for KRYS?+
The Street-high target is $403.00 (TD Cowen), and the Street-low is $284.00 (Guggenheim). The average of all 9 active targets is $349.22.
How many Wall Street analysts cover KRYS?+
10 analysts have an active rating on Krystal Biotech Inc, and 9 firms carry a live 12-month price target.
Who is the most accurate analyst covering KRYS?+
Among analysts who currently cover KRYS, Geulah Livshits of Chardan Capital has the strongest overall Quantellect track record (Rank #100). Their current call is Buy with a $323.00 target.
What is Krystal Biotech Inc's projected EPS for next quarter?+
The consensus estimate is $2.16 per share (range $1.42 – $4.12) across 8 analysts. Full-year EPS is projected at $8.21, rising to $9.87 the following year.
How much revenue is Krystal Biotech Inc expected to report next quarter?+
Consensus revenue is $134.7M (range $126.5M – $149.4M). Full-year revenue is projected at $516.0M, growing to $670.2M next year.
Have analysts been upgrading or downgrading KRYS lately?+
As of Jul, 9 of 10 firms rate KRYS a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their KRYS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
